Open original FDA record ↗Recall record
- FDA identifier
- Z-1277-2016
- Company in FDA record
- Roche Diagnostics Operations, Inc.
- FDA record creation date
- Mar 31, 2016
- First observed by MedTech Watch
- Nov 16, 2026
- Latest observed content change
- Nov 16, 2026
- Recall classification
- Class II
Reason stated in the source
Due to the risk of a recently identified cross reactivity, the Elecsys Estradiol assay should not be used when monitoring patient being treated with fulvestrant. Customers should be informed that fulvestrant will increase the apparent concentration of estradiol in women being treated with this drug. If treatment with fulvestrant has been altered or discontinued as a result of falsely elevated e
Source facts
- Action
- Roche sent an Urgent Medical Device Correction letter dated March 7, 2016 via UPS Ground (receipt required) to the consignee list. The letter identified the affected product, problem and actions to be taken. Consignees were instructed to complete the attached fax form and fax it to 1-866-891-1984. For questions contact the Roche Support Network Customer Support Center, 24 hours a day, seven days a week at 1-800-428-2336.
- Initiated
- 2016-03-07
- Root cause
- Device Design
- Terminated
- 2018-01-10
- Distribution
- US Nationwide Distribution including Puerto Rico.
- Recall number
- Z-1277-2016
- Recall status
- Terminated
- CDRH record ID
- 144234
- FDA record created
- 2016-03-31
- Recall event number
- 73411